Ionis Pharmaceuticals (Nasdaq: IONS) and partner Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE